Last month, the American Culture for Artificial Internal Organs (ASAIO) 68th Annual Fulfilling was successfully held in San Francisco. magAssist's product, BreathMo ® was highlighted in the conference.
Dr. Dong Guo from Beijing Anzhen Hospital, presented the innovation of the gadget included in a research titled "A 14-Day In-Vivo Evaluation of a Newly Developed Maglev ECMO System BreathMo ®, "demonstrating its efficiency and safety and security for providing both pulmonary and cardiac assistance.
A life-saving device that experienced rapid growth with 40% CAGR in China
Extracorporeal Membrane Oxygenation (ECMO) offers necessary assistance for intensive care unit (ICU) clients, 60% of whom establish heart or respiratory system failing with a death rate of 23-75%. In China, ECMO has ended up being a vital mechanical blood circulation assistance (MCS) for critically ill clients with information revealing that the variety of ECMO instances has increased practically fourfold from 2,826 in 2017 to 10,656 in 2021. (Data from the China ECMO Report 2021 and the survey of the Extracorporeal Life Support Committee of the Chinese Medical Doctor Association).
The expanding need for ECMO is additionally sustained by the COVID-19 pandemic, throughout which long term ECMO assistance was commonly used to treat those who experience serious signs and symptoms. The constraint of the existing ECMO systems revealed the demand for clinical tool manufacturers to upgrade ECMO devices equipped with advanced functions. These features include a full maglev pump with higher hemocompatibility, an oxygenator with high gas exchange efficiency and low cross-oxygenator pressure drop, aiming to supply long-lasting life-saving assistance to individuals in requirement.
The recently established ECMO, providing higher efficiency and security.
During the seminar, Dr. Guo explained that it is necessary to establish ECMOs with full maglev centrifugal pumps, which may better support clients over time. The full maglev centrifugal pumps have emerged as a highly promising remedy, supplying premium hemocompatibility, and offering possible design advancements for long-lasting ECMO or membrane layer applications.
Centrifugal blood pumps are often used in adult ECMO, and most of them rely on pivot bearing, which has a reduced hemocompatibility compared to complete maglev pumps. Moreover, the high rotational rate can trigger high shear tension, potentially leading to hemolysis.
A journal post in Medicine and Novel Technology and Devices analyzed the hemolytic performance of pumps in grown-up ECMO assistance, which highlighted the enhanced safety and security and performance of the full maglev flow modern technology. These computational searchings for were further sustained by speculative results, showing that the maglev pump triggered the least damage to blood cells when contrasted to the Revolution and Rotaflow pumps.
BreathMo ®, China's homemade maglev ECMO system that attends to the unmet medical demands of Chinese individuals.
To bridge professional spaces in China, magAssist has created a brand-new generation ECMO system, BreathMo ®. The use of maglev modern technology minimizes the risk of blood damages triggered by mechanical contact bearings, causing safer operation. The maglev pump demonstrates remarkable hemocompatibility with overall low blood damages at the hemolysis degree and degradation of high-molecular-weight (VWF).
As mentioned in the conference, the system's flow price of approximately 7L/min is complemented by an oxygenator that keep extraordinary efficiency, offering a low-pressure decrease (much less than 50mmHg) even at maximum circulation rates. Especially, the gadget incorporates an ultra-compact mobile console considering much less than 8 kg, enabling healthcare professionals to tailor therapy to individual patient requirements.
In the research study developed to assess the in-vivo efficiency and safety and security of BreathMo ®, the last health and wellness condition of the 10 sheep selected for the trial, with five going through VA cannulation and the remaining five going through VV cannulation, confirmed the system's capacity to give lung and heart support.
The research study exposed their plasma-free hemoglobin levels were within an appropriate array, with continually optimum oxygenator efficiency. The PFH values varied from 0.36 to 14.80 mg/dL, far listed below 40 mg/dL which is an indicator of feasible thrombus formation.
The autopsy assessments conducted after the research showed no issues, embolism, thrombus development, or end-organ damages, without any device-related adverse events reported, better verifying the system's safety and security profile and leading the way for its first-in-human studies test in the near future.
the new generation ecmo system The advancement of BreathMo ® marks an additional technical landmark as we seek new innovative life-saving services to improve individual health while encouraging medical care professionals to improve their treatment outcomes. With our ingenious maglev technology that allows for good hemocompatibility, BreathMo ® not only offers risk-free and efficient cardiopulmonary assistance however is additionally a brand-new encouraging beginning factor as we continue to leverage industry and technical resources to unlock new possibilities for the ECMO field," Dr. Chiahao Hsu, Senior Director of Science and Innovation Department of magAssist.